Abstract

Although Danhong injection (DHI) is the most widely prescribed Chinese medicine for both stroke and coronary artery disease (CAD), its underlying common molecular mechanisms remain unclear. An integrated network pharmacology and experimental verification approach was used to decipher common pharmacological mechanisms of DHI on stroke and CAD treatment. A compound-target-disease & function-pathway network was constructed and analyzed, indicating that 37 ingredients derived from DH (Salvia miltiorrhiza Bge., Flos Carthami tinctorii and DHI) modulated 68 common targets shared by stroke and CAD. In-depth network analysis results of the top diseases, functions, pathways and upstream regulators implied that a common underlying mechanism linking DHI’s role in stroke and CAD treatment was inflammatory response in the process of atherosclerosis. Experimentally, DHI exerted comprehensive anti-inflammatory effects on LPS, ox-LDL or cholesterol crystal-induced NF-κB, c-jun and p38 activation, as well as IL-1β, TNF-α, and IL-10 secretion in vascular endothelial cells. Ten of 14 predicted ingredients were verified to have significant anti-inflammatory activities on LPS-induced endothelial inflammation. DHI exerts pharmacological efficacies on both stroke and CAD through multi-ingredient, multi-target, multi-function and multi-pathway mode. Anti-endothelial inflammation therapy serves as a common underlying mechanism. This study provides a new understanding of DHI in clinical application on cardiovascular and cerebrovascular diseases.

Details

Title
Network pharmacology exploration reveals endothelial inflammation as a common mechanism for stroke and coronary artery disease treatment of Danhong injection
Author
Lyu, Ming 1 ; Chun-Lin, Yan 1 ; Hai-Xin, Liu 1 ; Tai-Yi, Wang 1 ; Xin-Hui, Shi 1 ; Jin-Ping, Liu 1 ; Orgah, John 1 ; Guan-Wei, Fan 2 ; Ji-Hong, Han 3 ; Xiao-Ying, Wang 4 ; Zhu, Yan 1 

 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese, Tianjin, China; Research and development center of TCM, Tianjin International Joint Academy of Biomedicine, Tianjin, China 
 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese, Tianjin, China; Research and development center of TCM, Tianjin International Joint Academy of Biomedicine, Tianjin, China; Medical Experiment Center, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China 
 College of Life Sciences, Nankai University, Tianjin, China 
 Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin University of Traditional Chinese, Tianjin, China; Massachusetts General Hospital, Harvard Medical School, Boston, USA 
Pages
1-18
Publication year
2017
Publication date
Nov 2017
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
1963433598
Copyright
© 2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.